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ERG  Electroretinogram 
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MSA-P Multiple system atrophy (parkinsonian subtype) 
PD  Parkinson’s disease 
PSP  Progressive supranuclear palsy 
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Abstract 
 
Multiple system atrophy (MSA) is a rare movement disorder and a member of the 
‘parkinsonian syndromes’ which also includes Parkinson’s disease (PD), progressive 
supranuclear palsy (PSP), dementia with Lewy bodies (DLB), and corticobasal 
degeneration (CBD). MSA is a complex syndrome in which patients exhibit a variety 
of signs and symptoms including parkinsonism, ataxia, and autonomic dysfunction. It 
can be difficult to separate MSA from the other parkinsonian syndromes but if ocular 
signs and symptoms are present they may aid differential diagnosis. Typical ocular 
features of MSA include blepharospasm, excessive square-wave jerks, mild to 
moderate hypometria of saccades, impaired vestibular-ocular reflex (VOR), 
nystagmus, and impaired event-related evoked potentials. Less typical features 
include slowing of saccadic eye movements, the presence of vertical gaze palsy, 
visual hallucinations, and an impaired electroretinogram (ERG). Aspects of primary 
vision such as visual acuity, colour vision, or visual fields are usually unaffected. 
Management of the disease to deal with problems of walking, movement, daily tasks, 
and speech problems is important in MSA. Optometrists can work in collaboration 
with the patient and health care providers to identify and manage the visual deficits of 
the patient. A more specific role for the optometrist is to correct vision to prevent 
falls and to monitor the anterior eye to prevent dry eye and control blepharospasm. 
 
Key words: Multiple system atrophy (MSA), parkinsonism, autonomic dysfunction, 
dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) 
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Introduction 
 
Multiple system atrophy (MSA) is a rare movement disorder and a member of a 
group of neurodegenerative diseases known as the ‘parkinsonian syndromes’. 
Characteristic of these syndromes is that patients exhibit the symptoms of 
‘parkinsonism’, viz. a range of problems involving movement, most typically 
manifest in Parkinson’s disease (PD) itself1, but also seen in progressive supranuclear 
palsy (PSP)2, and to some extent in dementia with Lewy bodies (DLB)3, and 
corticobasal degeneration (CBD).4  
 
MSA is derived from three previously described disease entities, viz. 
olivopontocerebellar atrophy, striato-nigral degeneration, and Shy-Drager syndrome.5 
These three diseases were originally regarded as distinct but are now considered to be 
subtypes of MSA.6 The classical symptoms of MSA include parkinsonism, ataxia, 
and autonomic dysfunction.6 Ataxia describes a gross lack of coordination of muscle 
movements while autonomic dysfunction involves a variety of systems that regulate 
unconscious bodily functions such as heart rate, blood pressure, bladder function, and 
digestion. It can be difficult to separate MSA from the other parkinsonian syndromes 
but if ocular signs and symptoms are present, then they may aid differential diagnosis. 
 
The main objectives of this review are: (1) to describe the general features of MSA, 
(2) to evaluate the visual signs and symptoms reported in the disorder, (3) to discuss 
those visual features which may help in differential diagnosis, and (4) to consider the 
role of the optometrist in managing the symptoms of the disease.  
 
General features 
 
Incidence 
 
The average annual incidence of MSA is 3.0/100,000 of the population and the 
median survival time 8.5 years7, an older age of onset being associated with a shorter 
survival time. The disorder is slightly more common in males than females 
(Male:Female ratio 1.3:1). Symptoms usually begin early in the fifth decade of life8 
and mean age of onset is 54.2 years (range 31 – 78 years).9 
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Signs and symptoms 
 
A list of the more common general signs and symptoms of MSA is shown in Table 1. 
The most consistent clinical syndrome is parkinsonism (87% of patients), followed by 
autonomic dysfunction (74%), cerebellar ataxia (54%), and pyramidal tract signs 
(49%).8 The most common sign at presentation is an akinetic-rigid syndrome 
resembling that of PD1, and observed in 62% of cases, while cerebellar ataxia and 
genito-urinary dysfunction are found in 22% and 9% of cases respectively. Erectile 
dysfunction may be one of the first signs in males.  
 
Of the autonomic system problems, urinary dysfunction is often more common and 
an earlier manifestation of the disease than orthostatic hypotension (postural low 
blood pressure).10 In addition to visual sensory symptoms, olfaction can be impaired 
in MSA, although deficits are usually less severe than in PD.8 Patients with either 
predominantly cerebellar signs or parkinsonism are regarded as distinct subtypes of 
MSA and designated as ‘MSA-C’ and ‘MSA-P’ respectively. Neuropsychiatric 
features, most usually depression, are present in about 40% of patients11 and such 
symptoms can also occur at presentation.12 There is a moderate intellectual 
impairment in some patients but severe loss of cognitive function is unusual and 
dementia is rare.8 MSA has a faster progression than PD and there is usually no 
remission from the disease.7 
 
Diagnosis  
 
The clinical diagnosis of MSA can be difficult owing to the overlap of clinical 
symptoms with other parkinsonian syndromes. ‘Consensus criteria’, i.e., those agreed 
by a panel of experts in the field have been established to diagnose MSA.13,14 Hence, 
the clinical symptoms of the disease are classified into four ‘domains’, viz., (1) 
autonomic and urinary dysfunction, (2) parkinsonism, (3) cerebellar ataxia, and (4) 
corticospinal dysfunction. A diagnosis of ‘possible’ MSA requires the presence of at 
least one of these criteria as a major feature plus at least two other features from 
separate domains. ‘Probable’ MSA requires the presence of autonomic failure, a poor 
response to the drug levodopa (L-dopa), and either the presence of parkinsonism or 
 6 
 
 
cerebellar ataxia. A diagnosis of ‘definite’ MSA, however, requires pathological 
confirmation at post-mortem.  
 
Gross neuropathology 
 
The cerebral cortex in MSA is usually significantly smaller than in control patients of 
similar age, the degree of atrophy reflecting disease duration rather than patient age.15 
There may be a specific and progressive cerebral atrophy affecting the frontal lobes16 
and the motor/premotor areas.17 In the cerebellum, pathology is more evident in the 
vermis than the hemispheres.18 In the midbrain, the substantia nigra and locus 
caeruleus are often pale due to loss of pigment. In addition, there may be atrophy and 
discolouration of the striatum specifically affecting the putamen, and this pathology is 
especially evident in the MSA-P subtype (Fig 1).  
 
Cellular pathology 
 
The cellular neuropathology of MSA is characterised by neuronal loss, gliosis, and 
myelin pathology affecting the putamen, caudate nucleus, external pallidum, 
substantia nigra, locus caeruleus, inferior olive, pontine nuclei, Purkinje cells of the 
cerebellum, and intermediate cell columns of the spinal cord6,8 (Fig 2). The most 
characteristic pathological change is the presence of abnormal protein aggregates, 
termed glial cytoplasmic inclusions (GCI) found mainly in oligodendrocytes and first 
described in 1989.19 This pathology affects the substantia nigra, striatum, inferior 
olivary nucleus, pontine nuclei, and cerebellum20 (Fig 3). The GCI comprise 
abnormal aggregations of silver-positive, 10-15nm diameter coated filaments, the 
major molecular constituent of which is the protein -synuclein. -Synuclein is also 
found in the Lewy bodies (LB) characteristic of PD1 and in DLB3 and unites these 
disorders with MSA as a major molecular group of neurodegenerative disease, viz. 
the ‘synucleinopathies’.21   
 
Causes 
 
The cause of MSA has not been established. Nevertheless, the abundance of -
synuclein-immunoreactive GCI in various brain areas suggests a fundamental defect 
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of the cytoskeleton affecting glial cells.22 Pathological changes in human patients, 
however, do not appear to have a simple genetic basis. No nucleotide alterations have 
been found to date in the entire coding region of the -synuclein gene in MSA. It is 
possible, however, that there could be mutations in the regulatory or intronic regions 
of the gene which could contribute to the cause of the disease.23 Two further genes 
have been implicated in MSA, viz., ZNF 231, a novel brain-specific gene encoding a 
nuclear protein involved in transcription elevation24 and (Src homology 2 domain 
containing) transforming protein 2 located on chromosome 19 (19p13.3), a gene 
involved in signal transduction.25 Allelic variation of the apolipoprotein E (APO E) 
gene, which may be a risk factor in DLB, does not appear to be involved in MSA.26 
Alternatively, it has been suggested that MSA may have an environmental cause, but 
there is little evidence to support this conclusion.27 
 
Treatment 
 
There are no treatments which will prevent the progression of MSA and treatment of 
the disorder often involves medication and life-style changes to help manage the 
symptoms. Three types of treatment are usually involved. First, corticosteroids such 
as fludrocortisone or minodrine are used to raise blood pressure. L-threo-
dihydroxyphenylserine, which is well tolerated by patients, can also be used for this 
purpose.28 Second, L-dopa and carbidopa are given to reduce the symptoms of 
parkinsonism, but not all MSA patients will be responsive. Third, treatments are used 
to manage difficulties in swallowing and breathing and to manage bladder care. Many 
of these treatments, especially those used to control parkinsonism, can have adverse 
ocular effects.1 Hence, patients treated with L-dopa and carbidopa may develop 
mydriasis followed by miosis, lid ptosis and blepharospasm. In the OPCA variant of 
MSA, there is a reduction in -amino-butyric acid (GABA) in the brain and cerebral 
spinal fluid.29 In two cases, treatment with gabapentin improved ataxia in one case 
while in the other, there was an improvement in severe cerebellar dysarthria and the 
patient also exhibited less oscillopsia and better vision.  
 
Visual signs and symptoms 
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Several of the brain areas affected in MSA are involved in visual function including 
the cerebral cortex, striatum, midbrain, and cerebellum (Fig 4). A variety of visual 
problems have therefore been reported in MSA and the major signs and symptoms are 
summarised in Table 2.  
 
Primary vision 
 
There is little detailed information concerning changes in visual acuity (VA) in MSA. 
Patients with other forms of parkinsonism1-3, however, often complain of poor vision 
especially as the disease progresses, and this may also be present in MSA. In PD, 
vision has been reported to be blurred in response to coloured stimuli30 with reduced 
colour fusion times.31 This response indicates loss of acuity of perception of 
monochromatic contours, but there is little evidence to date that colour vision is 
significantly affected in MSA. Consistent with this suggestion, abnormal visual 
evoked potentials (VEP) using coloured stimuli have not been reported.32 There have 
been few studies of visual field defects in patients with any parkinsonian syndrome; a 
consequence of the difficulties of testing patients with a movement disorder. A case 
of MSA has been reported, however, with enlarged blind spots but with no central 
scotoma.33 Some patients with neurodegenerative disease, in which impairment in 
VA have been demonstrated, also exhibit impairment of stereopsis as measured by 
random-dot stereograms34,35 but there is currently little information available for the 
parkinsonian syndromes. 
 
Eyelids and associated structures 
 
Given the autonomic dysfunction present in many MSA patients, problems with dry 
eye, blink reflex, and blepharospasm would be anticipated in MSA. Although not 
specifically observed in MSA, PD patients are prone to dry eye as a result of a 
combination of autonomic dysfunction and motor symptoms affecting blink rate.36 In 
addition, overall tear function abnormalities are significantly more common in PD 
including meibomian gland dysfunction.36 
 
Eyelid reflexes are impaired in parkinsonian syndromes, especially PSP2 including 
the ‘acoustic blink reflex’ and ‘acoustic startle reflex’, which are responses to a 
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sudden and unexpected sound involving a brief closing of the eye. In a 65-year-old 
female patient with MSA, blink reflexes were poor with impaired R2 response and 
enhanced recovery cycle which could be attributable to increased excitability of brain 
stem interneurons.37 
 
Blepharospasm is common in parkinsonian syndromes and more prevalent in 
‘atypical’ parkinsonism such as PSP and MSA.38,39 In addition, early and prominent 
blepharospasm in untreated patients with parkinsonism should raise a suspicion of the 
presence of MSA, PSP, or CBD.40 
 
Eye movement  
 
Eye movement problems including those of the eyelids are an important feature of the 
parkinsonian syndromes in general. For example, spontaneous and voluntary eyelid 
mobility are often abnormal in PSP but are usually less affected in PD and MSA.41 
Abnormal ocular fixation, however, may occur in a significant proportion of MSA 
patients.42 
 
In a patient with MSA, in which a combination of cerebellar and parkinsonian 
symptoms were present, the typical eye movement problems of PD were evident, viz., 
abnormal saccadic and smooth pursuit eye movements43, in combination with a 
vertical optokinetic nystagmus.44 By contrast, smooth pursuit and saccadic 
movements in the vertical direction were only slightly affected. Saccadic intrusions 
are continual movements that change position of the gaze during attempted fixation, 
and are often observed in MSA and other parkinsonian syndromes such as PSP.45,46 
Hence, in a recent study of oculomotor function in thirty MSA patients46, excessive 
square-wave jerks were observed in 21/30 patients, a mild supranuclear gaze palsy in 
8/30 patients, a gaze-evoked nystagmus in 12/30 patients, a positioning down-beat 
nystagmus in 10/25 patients, mild-moderate saccadic hypometria in 22/30 patients, 
impaired smooth pursuit movements in 28/30 patients, and reduced vestibulo-ocular 
reflex (VOR) suppression in 16/24 patients. By contrast, whereas convergence 
problems are likely to be observed in PD and some DLB patients, there is little 
evidence that they occur in MSA.47 
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Vestibulo-ocular reflex (VOR) 
 
The VOR is a reflex eye movement that stabilizes images on the retina during 
movements of the head. This is achieved by the brain inducing an eye movement in 
the opposite direction to that of the head. It can be tested by the ‘rapid head impulse 
test’ in which the head is rapidly moved to the side. Normally the eyes will continue 
to fixate in the same direction but in MSA, no compensatory eye movement is 
apparent. The ‘gain’ of the VOR is the ratio of the change in eye angle to head angle 
during a head turn. If the gain is impaired (ratio not equal to unity), head movements 
result in image motion on the retina and blurred vision. The gain of the VOR in the 
dark may be cancelled by fixation. Both MSA and PSP patients show this 
cancellation compared with both normal subjects and patients with PD42, a response 
which could be related to cerebellar dysfunction. VOR can result in oscillopsia in 
some patients with MSA.29 
 
Pupil reactivity 
 
Examination of the pupil is an opportunity to detect disturbances in autonomic 
function in MSA.48 Infra-red pupil pupillography can be used to measure several 
aspects of pupillary function such as pupil diameters in the light and dark, the light 
reflex response, and pupil reactions associated with the administration of 
pharmacological agents.48 In one study of pupil reactivity in MSA, about a quarter of 
patients tested had abnormal pupils and in the majority, the defects were bilateral and 
symmetrical. Pupil defects were not usually apparent to the patients themselves or to 
their physicians. In addition, in normal subjects, pupil size often increases in response 
to stress but no such change is apparent in MSA.49 ‘Horner’s syndrome’ (abnormally 
small pupil diameter) has rarely been observed, although such a change has been 
reported in one case of MSA.50 
 
Psychophysics 
 
Contrast sensitivity is affected in PD, at least in a proportion of patients51,52, but there 
is little evidence for a similar effect in MSA. For example, interocular differences in 
spatial contrast sensitivity have been observed in idiopathic PD but not in MSA.53 
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Visual spatial contrast threshold and suprathreshold contrast match to high-contrast 
sinewave gratings have been compared in PD and MSA patients and control 
subjects.54 The response of PD patients was affected compared with controls but this 
was not the case in MSA. Visuo-spatial function may therefore be largely spared in 
MSA.55   
 
Evoked potentials 
 
Evoked responses to motor stimuli have been reported to be normal in MSA.56 
Nevertheless, although significant effects on the electroretinogram (ERG) and VEP 
have been found in PD and PSP, the results reported in MSA have been more 
controversial. For example, the pattern reversal ERG to a coloured stimulus was 
recorded in both PD and MSA.32 Although reduced amplitude and increased latency 
of evoked components were observed in PD, especially when a blue-yellow 
horizontal grating was used as a stimulus, no such effects were observed in MSA.32 A 
negative ERG, however, has been observed in some patients with MSA-C.40 
Similarly, using a horizontal sinusoidal grating, there were no effects on the VEP in 
MSA although effects were demonstrated in PD.53 Significantly less impairment has 
also been observed in MSA to a full-field flash stimulus compared to PD and PSP.57 
Nevertheless, in some studies, VEP abnormalities have been reported in MSA with 
no detectable differences between the MSA-C and MSA-P subtypes.56 
 
Event-related evoked potentials 
 
There have been a number of studies of event-related potentials in MSA, which elicit 
the ‘P300’ evoked response, believed to reflect orientation, attention, stimulus 
evaluation, and memory. These evoked responses may be associated with neural 
activity in the temporal lobe, prefrontal lobe, limbic system, and thalamus.58 In one of 
the first studies of event-related potentials in MSA59, it was observed that the P300, 
elicited using visual stimuli, could be recorded even when a severe motor disability 
was present. In addition, reaction times to rare target stimuli were significantly 
decreased in PD and MSA compared with PSP.58 Moreover, Kamitani et al.60 studied 
event related potentials in both MSA-C and MSA-P, no significant change being 
found in the latency of the N1 or N2 components in either disease subtype suggesting 
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that the early stages of visual processing were preserved. Nevertheless, the P3a peak 
was less easy to distinguish and there were decreases in amplitude of the response in 
both MSA subtypes. By contrast, the P3b component was only affected in the MSA-C 
subtype and exhibited both increased latency and reduced amplitude. In a further 
study61, the N2 component was studied during selective attention to colour and was 
significantly delayed although the N1 component was clearly evident. The data 
suggest that the colour discrimination process may be impaired during selective 
attention in MSA. The reduced size of the pons, claustrum, perisylvian area, and the 
deep cerebral gray matter may be implicated in these responses.  
 
Complex visual functions 
 
Speech abnormalities are common in all parkinsonian syndromes including MSA, in 
which there is often a mixed dysarthria (problems in articulating speech) with ataxic 
and spastic elements.62 Maximum phonation time and reading speed are also affected 
but to a lesser extent than in PSP.62 The ‘room-tilt illusion’, a transient visuo-spatial 
perception problem, has been observed in MSA63, and may be caused by an erroneous 
cortical mismatch of visual and vestibular information. 
 
Sleep disorders and excessive daytime sleeping are common in MSA64 and may be 
caused by pathology affecting the regulation of the sleep/awake transition and the 
respiratory function. Sleep behavioural disorder episodes decrease in frequency but 
sleep becomes increasingly abnormal as the disease develops.65 There is also 
‘idiopathic rapid eye movement’ (iREM) disorder in MSA, characterised by abnormal 
behaviour during sleep accompanied with rapid eye movements, and which probably 
result from neuronal losses in the locus caeruleus and substantia nigra.66 There is also 
loss of neurons in the pedunculopontine and laterodorsal tegmental nuclei in MSA 
and DLB67 but these changes are unlikely to be the cause of the REM sleep disorder. 
So common is iREM in the parkinsonian syndromes generally, that it is often 
regarded as a strong indicator of the presence of a parkinsonian-type disorder. Visual 
hallucinations, unrelated to medication, are rare in MSA compared with the other 
parkinsonian syndromes and especially PD68 and may occur in only about 5-9% of 
patients.11 
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Differential diagnosis 
 
The parkinsonian syndromes exhibit overlapping signs and symptoms and therefore, 
can be difficult to distinguish with confidence. There are a number of general clinical 
features, however, that can help to distinguish MSA from PD, PSP, DLB, and CBD. 
First, patients with MSA often exhibit a combination of extrapyramidal, cerebellar, 
pyramidal, and autonomic dysfunction signs, many of which can be seen in other 
parkinsonian disorders. Second, MSA patients often show early autonomic problems, 
including those associated with pupil reactivity and urological failure, signs which 
are less likely to be observed in the other disorders.8 Third, imaging studies may also 
help to distinguish these disorders. Hence, PSP may be separated from MSA because 
it often exhibits atrophy of the midbrain/tegmentum on magnetic resonance imaging 
(MRI).69 Fourth, regional cerebral blood flow (rCBF) in the left frontal eye field is 
lower in PD compared with other parkinsonian syndromes such as MSA. Fifth, 
growth hormone responses may also help to distinguish MSA-P from PD, responses 
being generally greater in MSA than in the other syndromes. Specifically, the 
response to clonidine is greater than that to arginine, but combined response to both 
agents may have even greater sensitivity and specificity.70 
 
Where visual signs and symptoms are present, they can provide additional 
information for differential diagnosis. There is little current information relating each 
visual symptom to stage of the disease. However, pupil reactivity due to autonomic 
dysfunction, is likely to be an early feature of MSA in a proportion of cases40 while 
most other features are more likely to develop later in the disease. Hence, the 
presence of visual hallucinations, unrelated to medication, is rare in MSA compared 
with PD and DLB and their presence can often exclude MSA as a possible 
diagnosis.71 In addition, there is greater retinal pathology in PD, which results in 
significant defects in contrast sensitivity and in the early components of the VEP, 
which are not likely to be present in MSA. Moreover, colour VEPs are affected in PD 
but not in MSA.32 Nevertheless, where defects in the VEP are observed in MSA, they 
are more likely to involve event-related evoked potential and components such as the 
P300.58,59 
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Eye movement problems, especially those related to oculomotor dysfunction, are an 
important feature of MSA. Nevertheless, many of the visual signs and symptoms 
associated with eye movement in MSA are controversial and may not occur in all 
patients. Some authors believe that oculomotor anomalies are not present in MSA 
consistently enough to be useful in differential diagnosis.72 Additional features which 
may be useful include fixation, which is abnormal in a significant proportion of 
patients with PSP and MSA but less so in PD42, eyelid mobility which is abnormal in 
PSP but more likely to be normal in PD and MSA41, and the slowing of saccadic 
movements, especially in the vertical direction, which occurs most significantly in 
PSP.73 In addition, patients with PSP exhibit large saccadic intrusions which are 
visible in the absence of a fixation target while in MSA there are increasing saccadic 
intrusions with or without a visible target.74 Eye movements recorded during 
sinusoidal tracking by video-oculography75 show that in MSA, saccades correct for 
position error (‘catch-up saccades’) while in PD, saccades are directed towards future 
target positions (‘anticipatory saccades’). Fixation instability is a significant feature 
of PSP and MSA and is less often seen in PD and DLB. 
 
Anderson et al.46 have published a list of ‘red flag’ criteria which are strongly 
suggestive of a diagnosis of MSA and which include excessive square-wave jerks, 
mild to moderate hypometria of saccades, impaired VOR, and nystagmus. By 
contrast, if clinically slow saccades are present together with a moderate to severe 
vertical gaze palsy, the diagnosis is more likely to be one of the other parkinsonian 
syndromes, most probably PSP. However, caution in the use of many of these criteria 
has been advised in the diagnosis of MSA.76 An additional feature that may be useful 
in diagnosis is that in PD, there is often lateral jaw movement ipsilateral to the 
direction of horizontal gaze (ocular jaw synkinesia)77 while its absence would suggest 
MSA. 
 
MSA and the optometrist 
 
Middle-aged to elderly patients, who have not been diagnosed with MSA, may 
exhibit visual signs and symptoms suggestive of one of the parkinsonian-type 
disorders. The most important visual signs of MSA include oculomotor dysfunction 
and pupil reactivity, but with relatively preserved primary vision. Hence, a patient 
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with a combination of these features, together with autonomic or cerebellar 
dysfunction, should be referred for neurological examination.  
 
The following tests and procedures may be useful in identifying the visual problems 
of a patient with MSA. It is particularly important to carry out the full examination 
including ocular health assessment. It should be noted, however, that such patients 
may have problems in describing their symptoms and are often ‘tolerant’ of their 
visual problems.78 Hence, clinical examination requires sensitivity to the physical and 
mental state of the patient and the problems involved in the parkinsonian syndromes 
in general have been described in detail by Naylor.79 Subsequently, several additional 
tests may be helpful such as regular assessment of the general health of the exterior 
eye as dry eye, impaired blink reflex, and blepharospasm may be present. In addition, 
various aspects of oculomotor function should be assessed where possible as square-
wave jerks, supranuclear gaze palsy, a gaze-evoked nystagmus, a positioning down-
beat nystagmus, saccadic hypometria, impaired smooth pursuit movements, and 
reduced vestibulo-ocular reflex (VOR) suppression may all be present.  
 
Management of the disease to deal with problems of walking, movement, daily tasks, 
and speech problems is important in MSA. Optometrists can work in collaboration 
with the patient and health care providers to identify and manage the specific visual 
deficits of the patient. Management may involve physiotherapy to maintain mobility 
and prevent contractures, gait-training to improve mobility and decrease the risk of 
falls, and the use of social workers and occupational therapists to oversee the 
provision of equipment and home adaptation. Poor vision assumes a greater 
importance as mobility decreases with age. Hence, nuclear cataract can increase the 
risk of falling independent of age80, poor binocular vision is often associated with 
social isolation81, and unilateral visual loss with reductions in quality of life.82 These 
problems are likely to be even greater in patients with MSA who can potentially 
develop a range of visual problems during the course of the disease, many of which 
are common to other types of parkinsonian syndromes.1-3 Visual deficits in 
parkinsonian-type syndromes are often important in influencing overall motor 
function. Hence, identifying and correcting the visual problems as far as possible can 
significantly reduce the chances that MSA patients will suffer serious falls. In 
addition, the external eye should be monitored as blepharospasm and possibly dry eye 
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may be present. Hence, in a 65-year-old female with MSA, the patient was found to 
be functionally blind due to blepharospasm.37 These symptoms should be investigated 
as blepharospasm is an essentially treatable visual feature of parkinsonian syndromes 
such as MSA.  
 
Some of the visual problems observed in these patients may be adverse reactions to 
treatment. Side effects may occur relatively rapidly at the beginning of a treatment, or 
if medication has changed, but can also occur after a long latent period. It is 
important that those symptoms due to adverse reactions are separated from those due 
to the disease process itself. If ocular side effects are identified in a patient with MSA 
and become severe, then it is essential that these are monitored and the patient 
referred back to their physician for further clinical assessment.  
 
Conclusions 
 
Multiple system atrophy (MSA) is a complex syndrome in which patients exhibit a 
variety of signs and symptoms including those of parkinsonism, ataxia, and 
autonomic dysfunction. The most important visual signs of MSA include oculomotor 
and pupil reactivity dysfunction, but with relatively preserved primary vision. 
Nevertheless, the exact presentation of MSA is highly variable and patients can be 
visually asymptomatic. It is difficult to separate MSA from other disorders with 
parkinsonism such as PD and PSP. If ocular signs and symptoms are present, then 
they may aid differential diagnosis. Typical ocular features of MSA include excessive 
square-wave jerks, mild to moderate hypometria of saccades, impaired vestibular-
ocular reflex (VOR), and nystagmus. Less typical of MSA are slowing of saccades 
and the presence of vertical gaze palsy. Management of the disease to deal with 
problems of walking, movement, daily tasks, and speech problems is important in 
MSA. The optometrist can play an important role in this management both in 
ensuring that visual problems are corrected as far as possible and in referring patients 
to relevant health professionals. There is a more specific role for the optometrist in 
correcting vision to prevent falls and to monitor the anterior eye to prevent dry eye 
and control blepharospasm. 
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Table 1. Common signs and symptoms of multiple system atrophy (MSA) 
_____________________________________________________________________ 
Low blood pressure when standing up 
High blood pressure when lying down 
Impotence and loss of libido 
Loss of bladder or bowel control 
Rigidity of muscles 
Unsteady gait and loss of balance 
Reduction in perspiration, tears and saliva 
Impaired control of body temperature 
Constipation 
Slurred speech 
Visual disturbances 
Irregular heartbeat 
Impaired ability to swallow 
Difficulty in controlling emotions 
Agitated sleep 
Impaired breathing at night 
_____________________________________________________________________ 
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Table 2. Summary of visual signs and symptoms in Multiple system atrophy (MSA) 
_____________________________________________________________________ 
Ocular aspect  Change  in  MSA    Reference  
 
Primary vision Affected in other forms of parkinsonism 1-3 
   but little evidence in MSA 
 
Colour vision  Unlikely to be affected   30-32 
 
Eyelids and   May be dry eyes, impaired blink reflex, 36-40 
related structures and blepharospasm  
 
Eyelid mobility Spontaneous and voluntary eyelid mobility 41  
   normal       
 
Fixation  Abnormal in many patients   42 
 
Convergence  No problems reported    47 
 
Square-wave jerks Present in a significant proportion of  46 
   patients       
 
Supranuclear gaze Mild defect in some patients   46 
palsy          
 
Nystagmus  Gaze-evoked nystagmus in a proportion  46 
   of patients      
 
Saccadic hypometria Mild to moderate    46 
          
Smooth pursuit Impaired in a significant number of  46 
movement patients      
 
VOR Reduced suppression in a proportion of 46 
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Patients. May lead to oscillopsia    
       
Pupil reactivity Abnormal pupils in many patients,  48-50  
 No response due to stress    
 
Contrast sensitivity No evidence for impairment   53,54 
 
Visuo-spatial   Largely unaffected    55  
function  
 
ERG   Normal colour pattern ERG   56  
    Negative ERG in some patients  40 
           
VEP   Defects controversial    53 
   Normal        
    
Event-related  Abnormal P300 in some patients  58-61 
   
Sleep disorder  iREM in many patients   64-66 
 
Reading speed  Mildly affected    62 
          
Visual hallucinations Rare, unrelated to medication   13,68  
        
_____________________________________________________________________
Abbreviations: ERG = Electroretinogram, iREM = Idiopathic rapid eye movement 
sleep disorder, VEP = Visual evoked responses, VOR = Vestibulo-ocular reflex 
 
 30 
 
 
Legends to figures 
 
Fig 1. Coronal section of the brain of a patient with multiple system atrophy (MSA) 
showing the small and discoloured putamen (Put). Other abbreviations: CN = 
Caudate nucleus, GP = Globus pallidus, IC = Internal capsule, Th = Thalamus 
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Fig 2. The areas of the brain affected by the pathology of multiple system atrophy 
(MSA) (shown in bold in large font) (SFC = Superior frontal cortex, OC = Occipital 
cortex, STG = Superior temporal gyrus, PHG = Parahippocampal gyrus, HC = 
Hippocampus, CG = Cingulate gyrus, I/C = Insula/claustrum, A = Amygdala, nB = 
Nucleus basalis of Meynert, Put = Putamen, CN = caudate nucleus, P = Pulvinar of 
thalamus, SN = Substantia nigra, R = Raphe nuclei, LC = Locus careuleus, Other 
areas identified (in normal text and small font) (OG = orbital gyrus, GR = Gyrus 
rectus, PC = Parietal cortex, DG = Dentate gyrus, Th = Thalamus, LGN = Lateral 
geniculate nucleus, Hy = Hypothalamus, VT = Ventral tegmentum, Ce = Cerebellum, 
MB = Mamillary bodies, GP = Globus pallidus) superimposed on a two-dimensional 
model of the brain based on that of WJH Nauta and M Feirtag (1986) Fundamental 
Neuroanatomy. WH Freeman & Co. Hence the cerebral cortex is represented at the 
right of the diagram with the striatum (ST) and thalamus (Th) below. Midbrain and 
brain stem nuclei are at the left of the diagram 
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Fig 3. Mean density of glial cytoplasmic inclusions (GCI) in various brain regions in 
10 cases of multiple system atrophy (MSA). The greatest densities of GCI are seen in 
basal ganglia including the putamen (PT), globus pallidus (GP), and substantia nigra 
(SN). Significant numbers of GCI are also observed in the pons (PN), inferior olivary 
nucleus (ION), and cerebellum hemisphere (CB). Relatively low densities of GCI are 
observed in the superior frontal gyrus (SFG), superior temporal gyrus (STG), inferior 
temporal gyrus (ITG), parahippocampal gyrus (PHG), and hippocampus (HC). Data 
from Armstrong et al. (2004). Error bars indicate SE of mean 
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Fig 4. The major brain areas affected in multiple system atrophy (MSA) involved in 
visual function: Abbreviations: BG = Basal ganglia, CB = Cerebellum), ION = 
Inferior olivary nucleus, LC = Locus caeruleus, MC = Motor cortex, PMC = 
Premotor cortex, PT = Pontine nuclei, SC = Spinal cord, SN = Substantia nigra, Th = 
Thalamus  
 
 
